Molly Carr
Chief Medical OfficerDr. Molly Carr, M.D., is Chief Medical Officer of iBio, Inc. from July 31, 2026. Dr. Carr is an experienced physician with over many years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease. Dr. Carr lead the iBio’s global clinical strategy, medical affairs and regulatory initiatives as it advances its pipeline toward late-stage development. Prior to joining iBio, Dr. Carr held senior clinical development, medical affairs, business development and academic positions at leading biopharmaceutical companies and institutions, including Eli Lilly and Company, GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University and the University of Washington. She served as Clinical Head and Associate Vice President of Lilly’s Insulin and Glucagon Franchise, where she oversaw the company’s insulin portfolio and clinical development team, including the Phase 3 program for efsitora, a once-weekly insulin, as well as programs spanning prandial insulin, nasal glucagon, biosimilars and legacy insulins. Dr. Carr received a B.A. in Biology from Barnard College and an M.D. from Columbia College of Physicians and Surgeons. She is board certified in Endocrinology, Diabetes and Metabolism and Internal Medicine.
Positions
- Company NameiBio, Inc.Stock CodeIBIOPositionChief Medical OfficerColleagues
- MBMartin B. BrennerCEO, Chief Scientific Officer & Director
- WDWilliam D. ClarkIndependent Chairman
- FDFelipe DuranCFO & Principal Accounting Officer
- MBMarc BanjakChief Legal Officer & Corporate Secretary
- AKAlexandra KropotovaIndependent Director
- GLGary L. SenderIndependent Director
- DADavid A. ArkowitzIndependent Director
